Production (Stage)
Alnylam Pharmaceuticals, Inc.
ALNY
$318.32
$3.381.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -269.70M | -278.16M | -332.26M | -72.94M | -332.08M |
| Total Depreciation and Amortization | 45.59M | 44.70M | 46.24M | 42.74M | 41.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 488.83M | 426.39M | 416.31M | 481.41M | 444.76M |
| Change in Net Operating Assets | -309.83M | -201.24M | -73.74M | -78.94M | 34.94M |
| Cash from Operations | -45.11M | -8.31M | 56.56M | 372.26M | 189.12M |
| Capital Expenditure | -30.27M | -34.28M | -40.49M | -53.39M | -61.29M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 94.82M | -82.56M | -264.09M | -231.71M | -266.46M |
| Cash from Investing | 64.55M | -116.84M | -304.59M | -285.10M | -327.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 326.46M | 302.95M | 297.57M | 214.34M | 130.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -17.13M | -8.79M | 4.82M | 18.44M | 23.72M |
| Cash from Financing | 309.33M | 294.16M | 302.39M | 232.77M | 154.67M |
| Foreign Exchange rate Adjustments | 8.76M | -15.24M | 12.93M | -8.72M | -5.73M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 337.53M | 153.77M | 67.29M | 311.22M | 10.31M |